Faculty

Institution

Unit

Venue

Marcelo Vailati Negrao

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Thoracic Surgery

Department Of Thoracic-Head And Neck Med Onc

The University of Texas MD Anderson Cancer Center

Marcelo Vailati Negrao is a Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on thoracic oncology, specifically targeting KRAS G12C-mutant non-small cell lung cancer (NSCLC) through innovative trial designs, and investigating targeted therapies for BRAF V600E-mutant metastatic NSCLC. He also explores immunotherapy combinations, including bispecific T-cell engagers for small cell lung carcinoma, and studies intratumoral and circulating neutrophil-to-lymphocyte ratios as predictive biomarkers. His recent work includes leading the SUNRAY-01 trial and contributing to updated efficacy and overall survival analyses from the PHAROS study, published in the Journal of Clinical Oncology and Journal of Thoracic Oncology.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Marcelo Vailati Negrao

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology lung cancer thoracic oncology cancer research radiation oncology cancer treatment cancer care pharmacology immunology cancer immunotherapy medicinal research medicine oncogenes tumor biology cancer biology cancer genetics cancer genomics molecular cancer clinical research immunotherapy cellular therapy pharmacotherapy therapeutic targets cancer cells immune checkpoint inhibitors respiratory medicine bronchial neoplasm anti-cancer agents surgical oncology thoracic surgery tumor targeting cancer imaging cancer discovery therapeutic efficacy vascular biology cancer management novel therapies clinical radiation oncology tumor suppressors clinical mycology advanced nsclc medical mycology oncogenic agent radiation therapy cancer growth genitourinary cancers non-small-cell lung cancer jama oncology therapy resistance tumor heterogeneity drug targeting clinical immunology breast oncology cancer immunosurveillance gastrointestinal oncology cohort studies cardiovascular toxicity phase ii trial clinical outcomes cancer prevention oncologic imaging cardiovascular function lung adenocarcinoma immune checkpoint blockade adaptive immune system thoracic spine tumor mutational burden epithelial cell states resectable nsclc distinct patterns advanced solid tumors untreated cns metastases exercise training continuation therapy neoadjuvant chemotherapy oncogene-specific differences

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Plain Language Summary of the Updated Results From the Pharos Study: The Combination of Encorafenib Plus Binimetinib for People With Braf V600E-Mutant Metastatic Non-Small Cell Lung Cancer. Future Oncology (2026)

metastasislung cancerbronchial neoplasmoncologyradiation oncologyupdated resultscancer cellsoncogenesthoracic oncologycancer treatmenttherapeutic targetspharos studypathologyplain language summary

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity. JCO Precision Oncology (2026)

lung canceroncologyradiation oncologymetronomic chemotherapythoracic oncologypharmacologybrain tumor researchcancer treatmentreal-world experiencehigher neurologic toxicityintracranial efficacybronchial neoplasm

Sunray-01 Trial Protocol: An Innovative Study Design of Olomorasib and Pembrolizumab With or Without Chemotherapy in Kras G12C Nsclc. Future Oncology (2026)

cancer lettercancer immunotherapymedicinemetronomic chemotherapypharmacologytherapeutic targetsoncologycancer careinnovative study designcancer treatmentfuture medicinal chemistrycancer discoverydrug discoveryclinical trialsanti-cancer agentsimmune checkpoint inhibitorsmedicinal researchsunray-01 trial protocolmetronomic therapypharmacotherapy

95P: Adagrasib (Ada) Plus Cetuximab (Cetux) in Patients (Pts) With Advanced Krasg12C-Mutated Non-Small Cell Lung Cancer (Nsclc) From Krystal-1. Journal of Thoracic Oncology (2025)

lung cancercancer immunotherapyoncologyradiation oncologyimmune checkpoint inhibitorsoncogenesthoracic oncologycancer treatmentpathology

Abstract Ct209: Adagrasib (Ada) as First-Line Therapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (Nsclc) Harboring Kras G12Cand Stk11 Mutations: Krystal-1 Phase 2 Cohort. Cancer Research (2025)

lung cancerkrystal-1 phase 2oncologyradiation oncologymolecular cancerabstract ct209first-line therapyoncogenesthoracic oncologycancer treatmentcancer geneticspathology

Author Correction: Ctla4 Blockade Abrogates Keap1/Stk11-Related Resistance to Pd-(L)1 Inhibitors. Nature (2025)

Ferdinandos SkoulidisHaniel A. AraujoMinh Truong DoYu QianXin SunAna Galan CoboJohn T. LeMeagan MontesionRachael PalmerNadine JahchanJoseph M. JuanChengyin MinYi YuXuewen PanKathryn C. ArbourNatalie VokesStephanie T. SchmidtDavid MolkentineDwight H. OwenRegan MemmottPradnya D. PatilMelina E. MarmarelisMark M. AwadJoseph C. MurrayJessica A. HellyerJustin F. GainorAnastasios DimouChristine M. BestvinaCatherine A. ShuJonathan W. RiessCollin M. BlakelyChad V. PecotLaura MezquitaFabrizio TabbóMatthias SchefflerSubba DigumarthyMeghan J. MooradianAdrian G. SacherSally C. M. LauAndreas N. SaltosJulia RotowRocio Perez JohnsonCorinne LiuTyler StewartSarah B. GoldbergJonathan KillamZenta WaltherKurt SchalperKurtis D. DaviesMark G. WoodcockValsamo AnagnostouKristen A. MarronePatrick M. FordeBiagio RicciutiDeepti VenkatramanEliezer M. Van AllenAmy L. CummingsJonathan W. GoldmanHiram ShaishMelanie KierSharyn KatzCharu AggarwalYing NiJoseph T. AzokJeremy SegalLauren RitterhouseJoel W. NealLudovic LacroixYasir Y. ElaminMarcelo V. NegraoXiuning LeVincent K. LamWhitney E. LewisHaley N. KempBrett CarterJack A. RothStephen SwisherRichard LeeTeng ZhouAlissa PoteeteYifan KongTomohiro TakeharaAlvaro Guimaraes PaulaEdwin R. Parra CuentasCarmen BehrensIgnacio I. WistubaJianjun ZhangGeorge R. BlumenscheinCarl GayLauren A. ByersDon L. GibbonsAnne TsaoJ. Jack LeeTrever G. BivonaD. Ross CamidgeJhannelle E. GrayNatasha B. LeighlBenjamin LevyJulie R. BrahmerMarina C. Garassino

receptorscancer immunotherapykey sitepharmacologytranslational pharmacologymolecular pharmacologycellular therapyoncologyauthor correctionmedicinal chemistrydrug resistance analysissystems biologyfuture medicinal chemistrynon-pharmacological interventionsradiation oncologynovel therapiesvascular biologymedicinal researchenzyme inhibition

Braf V600E -Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of Erbb Receptor Signaling. bioRxiv (Cold Spring Harbor Laboratory) (2025)

Melanie DacheuxMeng-Jung WuMichael T ScherzerMonique NillsonBrandon MurphySophia SchumanZhenlin JuTrever BivonaPiro LitoMatthew GumbletonSonam PuriWallace AkerleyJing WangKaiwen WangJohn Victor HeymachConan G KinseyMarcelo V NegraoMartin McMahonAria Vaishnavi

lung cancertumor biologyligand-mediated activationoncologycancer biologycell signalingcancer cellsoncogenessystems biologybiochemistrymolecular biologytumor microenvironmenterbb receptormedicinal research

Data From First-Line Met Tyrosine Kinase Inhibitors Versus Immunotherapy ± Chemotherapy for Patients With Met Exon 14 Skipping Mutant Metastatic Nsclc. (2025)

metastasislung cancercancer immunotherapymet exon 14metronomic therapyoncologyradiation oncologymolecular cancermetronomic chemotherapyimmune checkpoint inhibitorsoncogenespharmacologycancer treatmentimmunotherapy ± chemotherapypharmacotherapy

First-Line Immunotherapy With or Without Chemotherapy Versus Braf Plus Mek Inhibitors for Patients With Braf V600E -Mutated Metastatic Non-Small Cell Lung Cancer: The Front-Braf Study.. Journal of Clinical Oncology (2025)

metastasislung cancercancer immunotherapybronchial neoplasmfront-braf studyoncologymolecular cancercancer cellsimmune checkpoint inhibitorsimmunotherapyimmunologythoracic oncologycancer treatmentchemotherapy versus braffirst-line immunotherapypathology

First-Line Immunotherapy With or Without Chemotherapy Versus Braf Plus Mek Inhibitors in Brafv600E-Mutated Metastatic Non-Small-Cell Lung Cancer (Front-Braf): A Multicentre, Retrospective Cohort Study. The Lancet Oncology (2025)

lung canceroncologyimmunotherapyimmunologythoracic oncologycancer treatmentbronchial neoplasm

1
2
3
4
5
17
10 / page

Marcelo Vailati Negrao

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Thoracic Surgery

Department Of Thoracic-Head And Neck Med Onc

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Marcelo Vailati Negrao

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

metastasislung cancerbronchial neoplasmoncologyradiation oncologyupdated resultscancer cellsoncogenesthoracic oncologycancer treatmenttherapeutic targetspharos studypathologyplain language summary

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity. JCO Precision Oncology (2026)

Sunray-01 Trial Protocol: An Innovative Study Design of Olomorasib and Pembrolizumab With or Without Chemotherapy in Kras G12C Nsclc. Future Oncology (2026)

95P: Adagrasib (Ada) Plus Cetuximab (Cetux) in Patients (Pts) With Advanced Krasg12C-Mutated Non-Small Cell Lung Cancer (Nsclc) From Krystal-1. Journal of Thoracic Oncology (2025)

lung cancercancer immunotherapyoncologyradiation oncologyimmune checkpoint inhibitorsoncogenesthoracic oncologycancer treatmentpathology

lung cancerkrystal-1 phase 2oncologyradiation oncologymolecular cancerabstract ct209first-line therapyoncogenesthoracic oncologycancer treatmentcancer geneticspathology

Author Correction: Ctla4 Blockade Abrogates Keap1/Stk11-Related Resistance to Pd-(L)1 Inhibitors. Nature (2025)

Braf V600E -Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of Erbb Receptor Signaling. bioRxiv (Cold Spring Harbor Laboratory) (2025)

Data From First-Line Met Tyrosine Kinase Inhibitors Versus Immunotherapy ± Chemotherapy for Patients With Met Exon 14 Skipping Mutant Metastatic Nsclc. (2025)

lung canceroncologyimmunotherapyimmunologythoracic oncologycancer treatmentbronchial neoplasm

1
2
3
4
5
17
10 / page